ViroPharma's Second Act: First a Tough One to Follow
In the year since biotech ViroPharma acquired Vancocin, it's transformed itself from a development-style biotech into an earnings-driven success. One result: a new shareholder base that likes regular profit increases and may not tolerate the lower margins that come with additional R&D spending or in-licensing costs. But with generics and other competitors on the near-term horizon, ViroPharma needs a dramatic second-act solution.
By Ellen Foster Licking
Just last fall, ViroPharma Inc. was in desperate circumstances. Its first product had failed to win approval from the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.
Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.